Fadlo R. Khuri, MD


Dr. Khuri is considered one of the leading translational clinical investigators and physicians in lung and aerodigestive medical oncology in the world.

Titles and Roles

Deputy Director
Winship Cancer Institute of Emory University
Professor and Chairman, Department of Hematology and Medical Oncology
Emory University School of Medicine
Executive Associate Dean of Research
Emory University School of Medicine
Medical Oncologist
Lung Cancer
Head and Neck Cancer
Thyroid Cancer
Phase I Clinical Trials Unit
Research Program
Discovery and Developmental Therapeutics


Fadlo R. Khuri, MD, is Professor and Chairman of the Department of Hematology & Medical Oncology, and Executive Associate Dean of Research at Emory University School of Medicine. He also serves as Deputy Director for the Winship Cancer Institute of Emory University. Dr. Khuri holds the Roberto C. Goizueta Distinguished Chair for Cancer Research. He is a Professor of Otolaryngology, Medicine, and Pharmacology, and he also serves as editor-in-chief of the journal Cancer.


Dr. Khuri earned his bachelor's degree from Yale University, in New Haven, CT, and his medical degree from Columbia University, College of Physicians and Surgeons, in New York, NY. He completed his residency in internal medicine at the Boston City Hospital, Boston University School of Medicine. He then completed a fellowship in hematology and medical oncology at the New England Medical Center, Tufts University School of Medicine. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of the American Association for Cancer Research, and the American Society of Clinical Oncology. He was on faculty at the University of Texas M.D. Anderson Cancer Center from 1995-2002 prior to joining Winship.


Dr. Khuri is the recipient of numerous awards, including being listed among America's Top Doctors and the Marquis Who's Who in the World. He is the recipient of a Georgia Cancer Coalition Distinguished Clinical Scholar Award. In 2013, he received the prestigious AACR Richard and Hinda Rosenthal Award for groundbreaking contributions in lung and aerodigestive medical oncology. In 2014, he was elected by his peers as an American Association for the Advancement of Science Fellow. He has been the recipient of competitive, peer-reviewed federal grant support from the National Cancer Institute, Department of Defense, and American Cancer Society over the last decade.


His research interests include development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with tobacco related cancers. His laboratory is investigating the mechanism of action of signal transduction inhibitors in tobacco related cancers.


He serves on the editorial boards of seven journals, including the Journal of Clinical Oncology, Clinical Cancer Research and Cancer, and has published over 100 peer reviewed articles in elite journals including Nature Medicine, Journal of the National Cancer Institute, Cancer Research and the Journal of Clinical Oncology.

Cascade Link